Ophthalmology

Part 3: Drs Sneha Sharma and Prerakkumar Parikh Quell Concerns About Ophthalmology Biosimilars

July 9th 2023

By Skylar Jeremias

Prerakkumar Parikh, PharmD, and Sneha Sharma, PharmD, from Magellan Rx Management, tackle some of the biggest concerns ophthalmologists have regarding emerging biosimilars for ophthalmic conditions, including interchangeability as well as lack of real-world evidence and education.

Biosimilarity Between SB11 and Lucentis for nAMD Further Supported

July 4th 2023

By Justina Petrullo

Article

Long-term results comparing ranibizumab biosimilar SB11 vs reference ranibizumab (Lucentis) on neovascular age-related macular degeneration (nAMD) support biosimilarity between the treatments.

Julie Reed: When the US Could See Meaningful Savings From Adalimumab, Ranibizumab Biosimilar Competition

June 25th 2023

By Skylar Jeremias

Video

Juliana (Julie) Reed, executive director of the Biosimilars Forum, predicts how long it will take for savings from adalimumab and ranibizumab biosimilar competition to fully manifest and how stakeholders can champion for better market competition for biosimilars.

Phase 3 Study Finds Ranibizumab Biosimilar Ximluci Equivalent to Lucentis in nAMD

June 23rd 2023

By Deana Ferreri, PhD

Article

The ranibizumab biosimilar XSB-001 (Ximluci) demonstrated biosimilarity to the originator (Lucentis) in a phase 3 trial in neovascular age-related macular degeneration (nAMD).

The Top 5 Biosimilar Articles for the Week of May 1

May 5th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of May 1, 2023.

Samsung Bioepis Shares 1-Year Phase 3 Results for Eylea Biosimilar

May 2nd 2023

By Skylar Jeremias

Article

At the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, Samsung Bioepis shared comparable safety, efficacy, and immunogenicity data through 1 year between its aflibercept biosimilar (SB15) and the originator (Eylea).

Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to Lucentis

April 28th 2023

By Justina Petrullo

Article

Biosimilar ranibizumab showed similar efficacy and safety in a recent study of the eyes of Indian patients with neovascular age-related macular degeneration.

Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval

April 26th 2023

By Skylar Jeremias

Article

Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.

SB11 Demonstrates Biosimilarity to Lucentis in Long-term Study in nAMD

April 22nd 2023

By Deana Ferreri, PhD

Article

A long-term follow-up of a phase 3 study comparing ranibizumab biosimilar SB11 to the reference product (Lucentis) in neovascular age-related macular degeneration (nAMD) found the similarity in efficacy end points reported early on was maintained through 52 weeks.

Real-World Study Suggests Comparable Efficacy Between Biosimilar Razumab and Originator in PCV

April 15th 2023

By Deana Ferreri, PhD

Article

A real-world study in India compared the ranibizumab biosimilar Razumab to the originator (Lucentis) in patients with polypoidal choroidal vasculopathy (PCV), finding that the biosimilar had comparable clinical outcomes.